Results 301 to 310 of about 27,891 (313)

Does Semaglutide Use Decrease Complications and Costs Following Total Knee Arthroplasty?

Journal of Arthroplasty, 2023
Vincent Yao
exaly  

Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2023
Beom Soo Shin, Soyoung Shin
exaly  

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations

Drug Design, Development and Therapy, 2022
Jena A Shaw, Anastassia Amaro
exaly  

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

Diabetes Care, 2022
Leigh Perreault, Melanie Davies, Juan Frias   +2 more
exaly  

Semaglutide as a promising antiobesity drug

Obesity Reviews, 2019
Georgios A Christou, Niki Katsiki, John E Blundell   +2 more
exaly  

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

European Journal of Pharmaceutical Sciences, 2017
Lene Jensen, Inga Bjørnsdottir
exaly  

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Diabetes Care, 2018
Andrew Ahmann, Francesco Dotta, Ildiko Lingvay   +2 more
exaly  

Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy

Journal of Clinical Anesthesia, 2023
exaly  

Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

Journal of Clinical Pharmacology, 2015
Christoph Kapitza, Lene Jensen, Anne Flint   +2 more
exaly  

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

Lancet, The, 2019
Richard E Pratley, Aslam Amod, Takashi Kadowaki   +2 more
exaly